select count(*) as counts from cancer where `biomolecule` LIKE '%Metabolite%'

Browse Biomarkers Based on Biomolecules

This page shows data for Metabolite biomolecule.
Total Entries Retrieved: 122
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
363 Lactate Metabolites Humans Upregulated (Benign: 0.61 ± 0.28 Vs Cancerous: 1.59 ± 0.61) Diagnostic Benign Vs Malignant p<0.0001 Tissue 18727052
364 Alanine Metabolites Humans Upregulated (Benign: 0.14 ± 0.06 Vs Cancerous: 0.26 ± 0.07) Diagnostic Benign Vs Malignant p<0.0001 Tissue 18727052
404 Total cholesterol Metabolites Humans Downregulated with Low Fat Diet [ Control Diet: 196 (95% CI: 180-226), Low Fat Diet: 182 (95% CI: 161-192)] Predictive Controls Vs Low Fat Supplementation in patients with PCa p = 0.048 Blood 19064574
405 Low-density cholesterol Metabolites Humans Downregulated with Low Fat Diet [ Control Diet: 111 (95% CI: 90-128), Low Fat Diet: 105 (95% CI: 90-124)] Predictive Controls Vs Low Fat Supplementation in patients with PCa p=0.032 Blood 19064574
414 4-OHE1(E2)-1-N7Gua Metabolites Humans Upregulated (PCA median: 0.7pmol/ml vs Control median: 0.3pmol/ml) Diagnostic Prostate Cancer Vs Controls p=0.0004 Urine 18816637
415 4-OHE1-1-N3Ade Metabolites Humans Upregulated (PCA median: 0.4pmol/ml vs Control median: 0.2pmol/ml) Diagnostic Prostate Cancer Vs Controls p=0.056 Urine 18816637
416 2-OHE1-6-N3Ade Metabolites Humans Upregulated (PCA median: 0.2pmol/ml vs Control median: 0pmol/ml) Diagnostic Prostate Cancer Vs Controls p=0.0014 Urine 18816637
448 Alkaline Phosphatase Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
449 LDH Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
450 Prostatic Acid Phosphatase (PAP) Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
451 Total Acid Phosphatase (TAP) Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
452 Albumin Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p=0.002 Blood 19505924
453 Hemoglobin Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
546 Sarcosine Metabolites Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0.011; Multivariate: p=0.015 Urine 20957673
550 Sarcosine Metabolites Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0.011; Multivariate: p=0.015 Urine 20957673
551 Total sialic acid Metabolites Humans Upregulated (mg/dL): (Controls: 6.25±3.49) Vs (Prostate Cancer: 15.1±4.83) Diagnostic Control Vs Cancer p<0.001 Serum 20973404
552 Total sialic acid Metabolites Humans Upregulated (mg/dL): (BPH: 7.24±4.56) Vs (Prostate Cancer: 15.1±4.83) Diagnostic BPH Vs Cancer p<0.001 Serum 20973404
663 Propenoic acid+ Pyrimidine+ Dihyroxybutanoic acid+Creatinine+ Purine+ Glucopyranoside+ Ribofuranoside+Xylonic acid=Xylopyranose Metabolites Humans Upregulated in PCA: (Propenoic acid, Dihyroxybutanoic acid, Creatinine and Xylonic acid); Downregulated in PCA: (Pyrimidine, Creatinine, Purine, Glucopyranoside, Ribofuranoside, Xylopyranose) Diagnostic Prostate Cancer Vs Healthy Men p<0.05 Urine 21626193
664 Dihyroxybutanoic acid + Pyrimidine + Xylonic acid + Xylopyranose + Ribofuranoside Metabolites Humans Upregulated in PCA: (Dihyroxybutanoic acid, Xylonic acid); Downregulated in PCA: (Pyrimidine, Xylopyranose, Ribofuranoside) Diagnostic PCa Vs Non Cancerous (healthy+BPH) p<0.05 Urine 21626193
681 Lactate Dehydrogenase (LDH) Metabolites Humans Upregulated with increasing PSA Prognostic progression Vs No Progression p= 0.014 Plasma 21723797
920 Deoxycarnitine; Acetylcarnitine; Hexanoylcarnitine; Octanoylcarnitine; Decanoylcarnitine; Laurylcarnitine; Palmitoylcarnitine; Stearoylcarnitine; Oleoylcarnitine; 3-hydroxybutyrate (BHBA); Acetoacetate; Dodecanedioate; Octadecanedioate; Metabolites Humans Differentially expressed [ Deoxycarnitine (0.89 fold); Acetylcarnitine (0.80 fold); Hexanoylcarnitine (0.80 fold_; Octanoylcarnitine (0.72 fold); Decanoylcarnitine (0.71 fold); Laurylcarnitine (0.65 fold); Palmitoylcarnitine (0.82 fold0; Stearoylcarnitine (0.77 fold); Oleoylcarnitine (0.88 fold); 3-hydroxybutyrate (BHBA) (0.36 fold); Acetoacetate (0.52 fold); Dodecanedioate (0.80 fold); Octadecanedioate (0.73 fold);] Predictive Effect of Androgen deprivation therapy (ADT) baseline to 3 months <0.05 Plasma 22589396
1057 Testosterone Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 4.62 ±1.48; After: 0.15 ± 0.1) Predictive Before and after androgen Deprivation therapy (ADT) p<0.001 Serum 23374809
1058 Dihydrotestosterone (DHT) Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 0.88 ±0.41 ; After: 0.05 ± 012) Predictive Before and after androgen Deprivation therapy (ADT) p<0.001 Serum 23374809
1059 Dehydroepiandrosterone sulfate (DHEA-S) Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 133.3 ±63.8; After: 83.4 ± 51.4) Predictive Before and after androgen Deprivation therapy (ADT) p<0.001 Serum 23374809
1060 Androstenedione Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 1.6 ±0.61 ; After: 0.83 ± 0.42) Predictive Before and after androgen Deprivation therapy (ADT) p<0.001 Serum 23374809
1061 3α-diol-G Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 26.4 ±6.9 ; After: 5.4 ± 7.1) Predictive Before and after androgen Deprivation therapy (ADT) p<0.001 Serum 23374809
1062 Insulin-like growth factor 1 (IGF-I) Metabolites Humans Upregulated with Androgen Deprivation Therapy (Before: 19.9 ±7.7 ; After: 22.2 ±9.1 ) Predictive Before and after androgen Deprivation therapy (ADT) p=0.001 Serum 23374809
1063 1,25(OH)2D Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 66.2 ±4.2 ; After: 59.7 ± 4.0) Predictive Before and after androgen Deprivation therapy (ADT) p=0.008 Serum 23374809
1115 Spermine; Putrescine; Cho; PCho; GPC; PE; Lactate; Alanine; Glucose; Citrate; Succinate; Glutamate; Glutamine; Glycine; Isoleucine; Leucine; Valine; Metabolites Humans Upregulated in Prostate Cancer [Cho; PCho; GPC; PE; Lactate; Alanine; Glutamate; Glutamine; Glycine; Isoleucine; Leucine; Valine;]; Downregulated in Prostate Cancer: [Spermine; Putrescine; Citrate; Creatine;] Diagnostic Normal adjacent samples Vs Cancer samples p<0.05 Tissue 23626811
1116 Spermine Metabolites Humans Downregulated in High Grade Prostate Cancer Diagnostic High Grade (GS >=7) Vs Low Grade (GS =6) p = 0.0044 Tissue 23626811
1117 Citrate Metabolites Humans Downregulated in High Grade Prostate Cancer Diagnostic High Grade (GS >=7) Vs Low Grade (GS =6) p = 0.000773 Tissue 23626811
1118 Citrate Metabolites Humans Downregulated in Gleason Score 7 Diagnostic Gleason Score 6 Vs Gleason Score 7 p = 0.014 Tissue 23626811
1119 Citrate Metabolites Humans Downregulated in Gleason Score 7 Diagnostic Gleason Score 6 Vs Gleason Score (8 & 9) p = 0.005 Tissue 23626811
1120 Spermine Metabolites Humans Downregulated in Gleason Score 7 Diagnostic Gleason Score 6 Vs Gleason Score (8 & 9) p = 0.022 Tissue 23626811
1127 Aminoadipic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1128 Cerebronic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1129 Gluconic acid Metabolites Humans Downregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1130 Glycerophosphoethanol-amine Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1131 2-Hydroxybehenic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1132 Isopentenyl pyrophosphate Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1133 Maltotriose Metabolites Humans Downregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1134 7-Methylguanine Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1135 Tricosanoic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1136 Aminoadipic acid Metabolites Humans Increased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.031 Tissue 23737455
1137 Gluconic acid Metabolites Humans Decreased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.036 Tissue 23737455
1138 Maltotriose Metabolites Humans Decreased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.006 Tissue 23737455
1139 Aminoadipic acid Metabolites Humans Increased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.048 Tissue 23737455
1150 1,5-anhydroglucitol; 10-heptaadecenoate (17:1n7); 10-nonadecenoate (19:1n9); ; 15-HETE; 1-arachidonoylglycerophosphoethanolamine; 1- arachidonoylglycerophosphoinositol; 1-arachidoylglycerophosphocholine; 1-eicosadienoylglycerophosphocholine; 1-heptadecanoylglycerophosphocholine; 1-heptadecanoylglycerophosphoethanolamine; 1-linoleoylglycerophosphocholine; 1-linoleoylglycerophosphoethanolamine; 1-myristoylglycerophosphocholine; 1-oleoylglycerol; 1-oleoylglycerophosphocholine; 1-oleoylglycerophosphoethanolamine; 1-oleoylglycerophosphoinositol; 1-oleoylglycerophosphoserine; 1-palmitoleoylglycerophosphocholine; 1-palmitoleoylglycerophosphoethanolamine; 1-palmitoylglycerol; 1-palmitoylglycerophosphocholine; 1-palmitoylglycerophosphoethanolamine 1-palmitoylglycerophosphoinositol; 1-palmitoylplasmenylethanolamine; 1-stearoylglycerol; 1-stearoylglycerophosphocholine; 1-stearoylglycerophosphoethanolamine; 1-stearoylglycerophosphoglycerol; 1-stearoylglycerophosphoinositol; 2-aminoadipate; 2-aminobutyrate; 2-arachidonoylglycerophosphocholine; 2-arachidonoylglycerophosphoethanolamine; 2-docosahexaenoylglycerophosphoethanolamine; 2-hydroxybutyrate; 2-hydroxyglutarate; 2-hydroxypalmitate; 2-hydroxystearate; 2-linoleoylglycerophosphocholine; 2-linoleoylglycerophosphoethanolamine; 2-methylbutyrylcarnitine; 2-oleoylglycerophosphocholine; 2-oleoylglycerophosphoethanolamine; 2-oleoylglycerophosphoserine; 2-palmitoylglycerophosphocholine; 2-palmitoylglycerophosphoethanolamine; 2-stearoylglycerophosphocholine; 3-(4-hydroxyphenyl)lactate; 3-aminoisobutyrate; 3-carboxy-4-methyl-5-propyl-2-furanpropanoate; 3-dehydrocarnitine; 3-dephosphocoenzyme-A; 3-hydroxybutyrate; 3-hydroxyhippurate; 3-indoxyl-sulfate; 3-phosphoglycerate; 4-acetamidobutanoate; 4-androsten-3beta_17beta-diol-disulfate-1; 4-hydroxybutyrate; 4-hydroxyhippurate; 4-methyl-2-oxopentanoate; 5,6-dihydrouracil; 5-alpha-androstan-3beta_17beta-diol-disulfate 5-methylthioadenosine; 5-oxoproline; 6-sialyllactose; 6-sialyl-N-acetyllactosamine; 7-alpha-hydroxy-3-oxo-4-cholestenoate; acetylcarnitine; acetylcholine; Ac-Ser-Asp-Lys-Pro; adenine; adenosine; adenosine 5'-diphosphate; adenosine 5'-monophosphate; adenosine 5'-diphosphoribose; adenosine 5-triphosphate; adenylosuccinate; adrenate (22:4n6); agmatine; alanine; alanylleucine; alanylphenylalanine; alanyltyrosine; alpha-glutamylvaline; alpha-hydroxyisovalerate; alpha-tocopherol; androsterone sulfate; arabitol; arabonate; arachidonate (20:4n6); arginine; ascorbate; asparagine; aspartate; aspartylleucine; aspartylphenylalanine; beta-alanine; beta-hydroxyisovalerate; betaine; butyrylcarnitine; caffeine; caproate (6:0); caprylate (8:0); carnitine; catechol-sulfate; C-glycosyltryptophan; chiro-inositol; cholesterol; choline; choline phosphate; cis-aconitate; cis-vaccenate (18:1n7); citrate; citrulline; coenzyme-A; creatine; creatinine; cysteine; cysteine-glutathione-disulfide; cysteinylglycine; cystine; cytidine; cytidine 5'-diphosphocholine; cytidine 5'-monophosphate; dehydroisoandrosterone sulfate; deoxycarnitine; dihomo-linoleate (20:2n6); docosadienoate (22:2n6); docosahexaenoate (22:6n3); docosapentaenoate (22:5n3); docosapentaenoate (22:5n6); docosatrienoate (22:3n3); eicosapentaenoate (20:5n3); ergothioneine; erythritol; erythronate; ethanolamine; flavin adenine dinucleotide; fructose; fucose; fumarate; galactose; gamma-aminobutyrate; gamma-glutamylalanine; gamma-glutamylglutamate; gamma-glutamylglutamine; gamma-glutamylleucine; gamma-tocopherol; gluconate; glucose; glucose 6-phosphate; glucose 1-phosphate; glutamate; glutamate, gamma-methyl ester; glutamine; glutarate; glutarylcarnitine; glutathione, oxidized; glutathione, reduced; glycerate; glycerol; glycerol 2-phosphate; glycerol 3-phosphate; glycerophosphoethanolamine; glycerophosphorylcholine; glycine; glycochenodeoxycholate; glycylisoleucine; glycylleucine; glycylproline; glycyltyrosine; glycylvaline; guanine; guanosine; guanosine-5-monophosphate; hexanoylcarnitine; hippurate; histamine; histidine; hydroxyisovaleroyl-carnitine; hypotaurine; hypoxanthine; inosine; inositol-1-phosphate; Isobar: 15-methylpalmitate, 2-methylpalmitate; Isobar: alpha-linolenate, gamma-linolenate (18:3n3 18:3n6); Isobar: dihomo-linolenate (20:3n3, 20:3n6); Isobar: dimethylarginine (ADMA, SDMA); Isobar: eicosenoate (20:1n9, 20:1n11); Isobar: fructose-1,6-diphosphate, glucose-1,6-diphosphate, myo-inositol-1,4-diphosphate, myo-inositol-1,3-diphosphate; Isobar: 13-HODE, 9-HODE; isobutyrylcarnitine; isocitrate; isoleucine; isoleucylisoleucine; isoleucylserine; isovalerylcarnitine; kynurenine; lactate; laurate (12:0); leucine; leucylglutamate; leucylleucine; leucylphenylalanine; leucylserine; linoleate (18:2n6); lysine; malate; maltose; maltotetraose; maltotriose; mannitol; mannose; margarate (17:0); mead acid (20:3n9); methionine; methyl-alpha-glucopyranoside; methylphosphate; myo-inositol; myristate (14:0); myristoleate (14:1n5); myristoylcarnitine; N1-methylguanosine; N2-methylguanosine; N-acetylalanine; N-acetylaspartate; N-acetyl-aspartylglutamate; N-acetylgalactosamine; N-acetylglucosamine; N-acetylglutamate; N-acetylmethionine; N-acetylneuraminate; N-acetylputrescine; N-acetyltryptophan; nicotinamide; nicotinamide adenine dinucleotide, reduced; nicotinamide adenine dinucleotide; nicotinamide ribonucleotide; nicotinamide riboside; nonadecanoate (19:0); octanoylcarnitine; oleate (18:1n9); oleoylcarnitine; ophthalmate; ornithine; palmitate (16:0); palmitoleate (16:1n7); palmitoylcarnitine; palmitoyl sphingomyelin; pantothenate; p-cresol sulfate; phenol sulfate; phenylacetylglutamine; phenylalanine; phenylalanylalanine; phenylalanylaspartate; phenylalanylglutamate; phenylalanylleucine; phenyllactate; phosphate; phosphoethanolamine; pipecolate; piperine; pregnen-diol-disulfate; pro-hydroxy-pro-proline; propionylcarnitine; prostaglandin I2; pseudouridine; putrescine; pyridoxate; pyroglutamine; pyroglutamylvaline; pyruvate; quinate; ribitol; riboflavin; ribose; ribulose; S-adenosylhomocysteine; sarcosine; scyllo-inositoll; serine; serotonin; serylleucine; serylphenylalanine; S-methylcysteine; sorbitol; spermidine; spermine; sphingosine ; stearate (18:0); stearoylcarnitine; stearoyl sphingomyelin; succinate; succinylcarnitine; taurine; theobromine; threonine; threonylisoleucine; threonylleucine; threonylphenylalanine; thymol sulfate; tiglyl carnitine; trans-4-hydroxyproline; tryptophan; tryptophan betaine; tyrosine; tyrsoylleucine; uracil; urate; urea; uridine; uridine 5'-monophosphate; valerylcarnitine; valine; valylmethionine; valyltyrosine; VGAHAGEYGAEALER; xanthine; xanthosine; xylitol; xylonate; xylulose; Metabolites Humans Differentially Expressed Diagnostic Prostate Cancer Vs Controls p<0.05 Tissue 23824564
1151 Histidine; Glycine; Alanine; Kynurenine; Glutamate; Glycerol 3-phosphate (G3P); Betaine; Pipecolate 2-methylbutyrylcarnitin; Isobar: 15-methylpalmitate; 2-methylpalmitate; Threonine; Cytidine 50-diphosphocholine; Valine; Myristoleate (14:1n5); S-adenosylhomocysteine (SAH); Phosphate; Choline; 2-aminobutyrate 2-hydroxypalmitate; Glycerol; Adenine; 2-hydroxystearate; Deoxycarnitine; Fumarate; Docosadienoate (22:2n6); Metabolites Humans Increased with Upgraded Gleason Score Prognostic Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8] p<0.05 Tissue 23824564
1152 Adenosine 50 -diphosphate (ADP); Citrate; Palmitoyl-sphingomyelin; Metabolites Humans Decreased with Upgraded Gleason Score Prognostic Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8] p<0.05 Tissue 23824564
1153 5,6-dihydrouracil +choline phosphate+ glycerol + methylpalmitate Metabolites Humans Differentially Expressed Prognostic Organ Confined Vs Non Orgnan Confined p<0.05 Tissue 23824564
1154 7-HOCA+ pregnen-diol disulfate +mannosyl tryptophan Metabolites Humans Differentially Expressed Prognostic Progression Free Survival (5 years) Vs No Progression Free Survival (5 years) p<0.05 Tissue 23824564
1369 Hyaluronan-Mediated Motility Receptor (HMMR) Metabolites Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.028; Multivariate: p=0.04 Tissue 24668563
1561 Linoleic Metabolites Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p=0.04 Tissue 8922296
1726 HA: Hyaluronic acid Metabolites Humans Upregulated in PCa (PCa: 239.6 (145.1–357.7); No PCa: 150.8 (51.8–264.1)) Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.004 Serum 30516927
1727 HA: Hyaluronic acid Metabolites Humans NA Prognostic High Risk Vs Intermediate Risk PCa p=0.0214 Serum 30516927
1728 HA: Hyaluronic acid Metabolites Humans Upregulated in Patient Reclassification Predictive Before and After Surgery Levels p=0.029 Serum 30516927
1774 Small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00070 Blood 30352818
1775 VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00056 Blood 30352818
1776 Cholesterol esters in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00058 Blood 30352818
1777 Cholesterol esters to total lipids ratio in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00062 Blood 30352818
1778 Cholesterol esters in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00002 Blood 30352818
1779 Cholesterol esters to total lipids ratio in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00111 Blood 30352818
1780 Cholesterol esters in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00107 Blood 30352818
1781 Cholesterol esters to total lipids ratio in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00139 Blood 30352818
1782 Free cholesterol in IDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00057 Blood 30352818
1783 Free cholesterol in large LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00080 Blood 30352818
1784 Free cholesterol in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00060 Blood 30352818
1785 Free cholesterol to total lipids ratio in medium HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00055 Blood 30352818
1786 Total cholesterol in HDL3 Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00109 Blood 30352818
1787 Total cholesterol in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00095 Blood 30352818
1788 Total cholesterol to total lipids ratio in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00105 Blood 30352818
1789 Total cholesterol in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.00001 Blood 30352818
1790 Total cholesterol to total lipids ratio in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00106 Blood 30352818
1791 Total cholesterol in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00132 Blood 30352818
1792 Total cholesterol to total lipids ratio in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00107 Blood 30352818
1793 Total cholesterol to total lipids ratio in small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00105 Blood 30352818
1794 Phospholipids in IDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00092 Blood 30352818
1795 Phospholipids to total lipids ratio in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00046 Blood 30352818
1796 Phospholipids to total lipids ratio in medium VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.00001 Blood 30352818
1797 Phospholipids in very small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00103 Blood 30352818
1798 Phospholipids to total lipids ratio in very small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00013 Blood 30352818
1799 Total lipids in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00035 Blood 30352818
1800 Triglycerides to total lipids ratio in medium VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00064 Blood 30352818
1801 Triglycerides to total lipids ratio small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00055 Blood 30352818
1802 Ratio of omega-6 Fatty Acids to total Fatty Acids Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00080 Blood 30352818
1803 Ratio of saturated Fatty acids to total Fatty acids Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00006 Blood 30352818
1804 Isoleucine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00008 Blood 30352818
1805 Leucine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00027 Blood 30352818
1806 Tyrosine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00003 Blood 30352818
1807 Valine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00139 Blood 30352818
1808 Albumin Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00065 Blood 30352818
1888 4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; 1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone Metabolites Humans Downregulated in PCa [SCO‐spondin (0.1 fold); Complement component C7 (0.1‐fold); Isoform 2 of Ankyrin repeat and SOCS box protein 18 (0.3‐fold); Gelsolin (0.3‐fold); Serum amyloid P-component (0.4‐fold); Ig heavy chain V‐I region V35 (0.5‐fold); Complement C1q subcomponent subunit C (0.5‐fold); Complement component C8 alpha chain (0.6‐fold); Isoform 2 of Filamin A (0.6‐fold); and Inter-alpha-trypsin inhibitor heavy chain H2 (0.7‐fold);] Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.05 Urine 30853355
2025 LPC(18∶1) Metabolites Humans Methylated in systemic Recurrence Diagnostic Patients Vs Controls 2.63E-09 Plasma 23152813
2026 LPC(20∶4) Metabolites Humans Methylated in systemic Recurrence Diagnostic Patients Vs Controls 1.71E-15 Plasma 23152813
2027 PC(40∶7) Metabolites Humans Methylated in systemic Recurrence Diagnostic Patients Vs Controls 4.37E-11 Plasma 23152813
2028 LPC(18∶0) Metabolites Humans Upregulated with fold change of 2.7 Diagnostic Patients Vs Controls 3.00E-08 Plasma 23152813
2029 LPC(16∶0) Metabolites Humans Upregulated with fold change of 3.2 Diagnostic Patients Vs Controls 2.03E-06 Plasma 23152813
2030 ePC(38∶4) Metabolites Humans Upregulated with fold change of 2.2 Diagnostic Patients Vs Controls 3.01E-08 Plasma 23152813
2031 PC(38∶4) Metabolites Humans Upregulated with fold change of 2.5 Diagnostic Patients Vs Controls 3.65E-05 Plasma 23152813
2032 PC(38∶5) Metabolites Humans Upregulated with fold change of 2.8 Diagnostic Patients Vs Controls 8.50E-06 Plasma 23152813
2033 SM(18∶1) Metabolites Humans Upregulated with fold change of 2.1 Diagnostic Patients Vs Controls 1.05E-09 Plasma 23152813
2034 SM(16∶1) Metabolites Humans Upregulated with fold change of 2.1 Diagnostic Patients Vs Controls 6.71E-09 Plasma 23152813
2035 DSM(16∶0) Metabolites Humans Upregulated with fold change of 2.2 Diagnostic Patients Vs Controls 3.85E-19 Plasma 23152813
2036 SM(16∶0) Metabolites Humans Upregulated with fold change of 3 Diagnostic Patients Vs Controls 1.20E-06 Plasma 23152813
2037 ePC(36∶1) Metabolites Humans Upregulated with fold change of 2.5 Diagnostic Patients Vs Controls 6.30E-10 Plasma 23152813
2038 SM(18∶0) Metabolites Humans Upregulated with fold change of 22.7 Diagnostic Patients Vs Controls 1.72E-06 Plasma 23152813
2039 ePC(36∶2) Metabolites Humans Upregulated with fold change of 2.5 Diagnostic Patients Vs Controls 1.72E-07 Plasma 23152813
2040 LPC(18:1)+LPC(20:4) Metabolites Humans Upregulated with fold change of 2.4 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2041 LPC(18:1)+LPC(20:4)+PC(40:7) Metabolites Humans Upregulated with fold change of 2.8 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2042 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0) Metabolites Humans Upregulated with fold change of 2 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2043 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0) Metabolites Humans Upregulated with fold change of more than 2 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2044 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4) Metabolites Humans Upregulated with fold change of more than 3 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2045 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4) Metabolites Humans Upregulated with fold change of more than 4 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2046 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5) Metabolites Humans Upregulated with fold change of more than 5 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2047 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1) Metabolites Humans Upregulated with fold change of more than 6 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2048 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1) Metabolites Humans Upregulated with fold change of more than 7 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2049 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0) Metabolites Humans Upregulated with fold change of more than 8 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2050 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0) Metabolites Humans Upregulated with fold change of more than 9 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2051 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1) Metabolites Humans Upregulated with fold change of more than 10 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2052 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1)+SM(18:0) Metabolites Humans Upregulated with fold change of more than 11 Diagnostic Patients Vs Controls <0.001 Plasma 23152813
2053 LPC(18:1)+LPC(20:4)+PC(40:7)+LPC(18:0)+LPC(16:0)+ePC(38:4)+PC(38:4)+PC(38:5)+SM(18:1)+SM(16:1)+DSM(16:0)+SM(16:0)+ePC(36:1)+SM(18:0)+ePC(36:2) Metabolites Humans Upregulated with fold change of more than 12 Diagnostic Patients Vs Controls <0.001 Plasma 23152813